"THE APPLICATION OF MIRAPEX PD EXTENDED-RELEASE IN MONOTHERAPY MODE IN THE EARLY STAGES OF PARKINSON'S DISEASE IN THE REPUBLIC OF UZBEKISTAN."
Abstract
Parkinson's disease, one of the most common neurodegenerative diseases, affects approximately 8.5 million people worldwide. Over the past 25 years, the prevalence of the disease has doubled. In 2019, the disease resulted in 5.8 million disability-adjusted life years, which is 81% more compared to 2000. In 2019, around 329,000 deaths from this disease were recorded, which is also twice as many as in 2000.
References
1. Belousov D.Yu., Afanasyeva E.V. Pharmacoeconomic analysis of the use of prolonged-release pramipexole in monotherapy for early stages of Parkinson’s disease | Belousov | Quality Clinical Practice No. 1, 53-64, 2015.
2. Illarionov S.N. Parkinson’s Disease and Movement Disorders: A Guide for Physicians / Ed. by Illarionov S.N., Leniv O.S. M., 2011. p. 41.
3. Karabanov A.V., Illarionov S.N. Experience with Mirapex PD in Parkinson’s disease. "Clinical Medicine" 2019.
4. Shtok V.N. “Extrapyramidal Disorders: A Guide to Diagnosis and Treatment” M., 2022.
5. Braak H. et al. // Neurobiol. Aging. 2003. V. 24. P. 197.
6. Gu M. et al. // J. Neurochem. 2020. V. 91. P. 1075.
8. IMS Health, 2014, http://www.imshealth.com
9. Lautertani F., Giallauria F., Testa C., Zinni C., Lorenzi B. Dopamine Pharmacodynamics: New Insights. Int. J. Mol. Sci. 2024, 25(10), 5293.
10. Ray N.J. et al. // Neurobiol. Dis. 2012. V. 48. P. 519.
11. Sharma P., Kishore A., Indranil De, Swarnima Negi, Kumar G., Bhardwaj S., Singh M. Mitigating Neuroinflammation in Parkinson's Disease: Exploring the Role of Proinflammatory Cytokines and the Potential of Phytochemicals as Natural Therapeutics. Neurochemistry International, Vol. 170, November 2023, 105604.
12. Ray N.J. et al. // Neurobiol. Dis. 2012. V. 48. P. 519.
13. World Health Organization DAIRY. https://www.who.int/data/gho/indicator-metadata-registry/imr-details/158
